Prognostic Factors in Patients with Non-small Cell Lung Carcinoma and Brain Metastases: a Malaysian Perspective

Tang, Weng Heng; Alip, Adlinda; Saad, Marniza; Phua, Vincent Chee Ee; Chandran, Hari; Tan, Yi Hang; Tan, Yan Yin; Kua, Voon Fong; Wahid, Mohamed Ibrahim; Tho, Lye Mun

추천

검색

자료유형: 학술저널

저자정보: Tang, Weng Heng (Clinical Oncology Unit, University of Malaya Medical Centre) Alip, Adlinda (Clinical Oncology Unit, University of Malaya Medical Centre) Saad, Marniza (Clinical Oncology Unit, University of Malaya Medical Centre) Phua, Vincent Chee Ee (Clinical Oncology Unit, University of Malaya Medical Centre) Chandran, Hari (Neurosurgical Unit, University of Malaya Medical Centre) Tan, Yi Hang (Beacon Cancer Hospital) Tan, Yan Yin (Beacon Cancer Hospital) Kua, Voon Fong (Beacon Cancer Hospital) Wahid, Mohamed Ibrahim (Beacon Cancer Hospital) Tho, Lye Mun (Beacon Cancer Hospital)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제5호

발행연도: 2015.1

수록면: 1,901 - 1,906 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Brain metastases occur in about 20-40% of patients with non-small-cell lung carcinoma (NSCLC), and are usually associated with a poor outcome. Whole brain radiotherapy (WBRT) is widely used but increasingly, more aggressive local treatments such as surgery or stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT) are being employed. In our study we aimed to describe the various factors affecting outcomes in NSCLC patients receiving local therapy for brain metastases. Materials and Methods: The case records of 125 patients with NSCLC and brain metastases consecutively treated with radiotherapy at two tertiary centres from January 2006 to June 2012 were analysed for patient, tumour and treatment-related prognostic factors. Patients receiving SRS/SRT were treated using Cyberknife. Variables were examined in univariate and multivariate testing. Results: Overall median survival was 3.4 months (95%CI: 1.7-5.1). Median survival for patients with multiple metastases receiving WBRT was 1.5 months, 1-3 metastases receiving WBRT was 3.6 months and 1-3 metastases receiving surgery or SRS/SRT was 8.9 months. ECOG score (${\leq}2$ vs >2, p=0.001), presence of seizure (yes versus no, p=0.031), treatment modality according to number of brain metastases (1-3 metastases+surgery or $SRS/SRT{\pm}WBRT$ vs 1-3 metastases+WBRT only vs multiple metastases+WBRT only, p=0.007) and the use of post-therapy systemic treatment (yes versus no, p=0.001) emerged as significant on univariate analysis. All four factors remained statistically significant on multivariate analysis. Conclusions: ECOG ${\leq}2$, presence of seizures, oligometastatic disease treated with aggressive local therapy (surgery or SRS/SRT) and the use of post-therapy systemic treatment are favourable prognostic factors in NSCLC patients with brain metastases.

#Non-small cell lung carcinoma #brain metastases #stereotactic radiosurgery #Cyberknife

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!